Delving into the Latest Updates on Oxandrolone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxandrolone (JAN/USP/INN), NSC-67068, SC-11585

+ [4]

Target

AR

Mechanism

AR agonists(Androgen Receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

OstealgiaWeight Loss

Inactive Indication-

Originator Organization

Gemini Laboratories LLC

Active Organization

Gemini Laboratories LLC

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (21 Jul 1964),

OstealgiaWeight Loss

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC19H30O3

InChIKeyQSLJIVKCVHQPLV-PEMPUTJUSA-N

CAS Registry53-39-4

This study is about healing after a rmultiligament knee reconstruction procedure. We hope to learn if a biologic medication: Oxandrolone, a synthetic derivative of the human hormone Testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.

Start Date01 Jul 2023

Sponsor / Collaborator

University of Southern California

NCT05516849 / WithdrawnPhase 3IIT

Placebo Versus Oxandrolone Supplementation in Trauma: A Randomized Multi-Center Double Blind Clinical Trial in High-Energy Lower Extremity Trauma (POST-Injury Trial)

The primary aim of this study is to examine the effect of Oxandrolone supplementation after lower extremity high energy fracture on muscle volume recovery. As Oxandrolone supplementation has never been examined in this patient population, the primary null hypothesis is that there will be no difference in measured thigh muscle mass volume between Oxandrolone supplementation and placebo administration groups.

Start Date19 May 2022

Sponsor / Collaborator

Sunnybrook Health Sciences Centre

[+2]

100 Clinical Results associated with Oxandrolone

Login to view more data

100 Translational Medicine associated with Oxandrolone

Login to view more data

100 Patents (Medical) associated with Oxandrolone

Login to view more data

508

Literatures (Medical) associated with Oxandrolone

22 Nov 2024·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Recalcitrant lipodermatosclerosis with ulceration treated with oxandrolone and pentoxifylline

Article

Author: Chan, Jonathan J ; Chen, Jacqueline ; Mei, Angela

Herein we describe the case of a 73-year-old woman with a 15-year history of advanced lipodermatosclerosis with progressive ulceration despite extensive multidisciplinary treatment with compression therapy, surgical venous ablation, topical corticosteroids, antibiotics and hyperbaric oxygen therapy. She was commenced on oxandrolone and pentoxifylline. After 5 months, complete healing of the ulcer was observed without significant adverse effects or hepatotoxicity. Oxandrolone may serve as an effective and safe treatment for ulcerated wounds secondary to advanced lipodermatosclerosis.

01 Nov 2024·Singapore medical journal

Use of testosterone replacement therapy in the rehabilitation of patients with intensive care unit-associated weakness and hospital-associated deconditioning: the Singapore General Hospital rehabilitation experience

Article

Author: Samuel, Geoffrey Sithamparapillai ; Swee, Du Soon

Abstract:

Introduction::

Rehabilitation medicine in a tertiary care hospital involves attending to many patients affected by intensive care unit (ICU)-associated weakness (ICU-AW) and hospital-associated deconditioning (HAD). These conditions contribute to poor long-term functional outcomes and increased mortality. We explored the role of short-term adjunctive androgen therapy in this group of patients in improving the rehabilitative outcomes.

Methods::

This was a retrospective analysis of five patients with either ICU-AW or HAD who were given testosterone replacement therapy (TRT) or oxandrolone for a total of 2 weeks during the period from April to November 2020 was undertaken. During the 2-week trial period, the subjects underwent standard rehabilitation therapy.

Results::

Grip strength was used as the primary outcome measure, and the mean improvement was 4.2 kg (+24.9%), which is encouraging in a 2-week timeframe. This was matched with good functional recovery in terms of distance ambulated and less assistance needed for ambulation. Sex hormone analysis was also done before initiation of TRT, and it showed that four out of five of the subjects were biochemically hypogonadal. None of the subjects dropped out or experienced any significant adverse events over the 2-week trial period. All the subjects except one improved to full independence at 3 months post-discharge.

Conclusion::

TRT has the potential to be used as a useful adjunct to standard rehabilitation in enhancing functional recovery in critically ill patients. A multidisciplinary approach would ensure that suitable patients benefit from optimal nutrition, optimal rehabilitation and synergistic testosterone therapy in a clinically sound and resource-efficient fashion.

01 Oct 2024·Jornal de Pediatria

Growth charts of Brazilian girls with Turner syndrome without the use of GH or oxandrolone

Article

Author: Morcillo, André Moreno ; Carpini-Dantas, Stela ; Guerra-Junior, Gil ; de Lemos-Marini, Sofia Helena Valente ; Vieira, Tarsis Paiva ; Baptista, Maria Tereza Matias ; Lopes, Carolina Paniago ; Marmo, Denise Barbieri ; Maciel-Guerra, Andréa Trevas

OBJECTIVE:

The development of specific growth charts for Turner Syndrome (TS) promotes adequate assessment of growth and weight gain, and earlier diagnosis of comorbidities, and may help to analyze the effectiveness of treatments to promote growth and puberty. The aim of this study was to construct a growth chart with the largest possible series of patients with a cytogenetic diagnosis of TS from a Brazilian reference center.

METHODS:

This is a longitudinal study, with 259 cases of TS born between 1957 and 2014 and followed between 1975 and 2019, without the use of GH or oxandrolone. 3,160 height measurements and 2,918 wt measurements were used, with subsequent calculation of the Body Mass Index (BMI). For data analysis, the "GAMLSS" package of the "R" software was used.

RESULTS:

The mean target height was 157.8 cm (standard deviation 5.2; median 160.4 cm). The mean height of patients with TS at 20 years of age was 145.6 cm (standard deviation 5.9; median 146.7 cm). Height, weight, and BMI by age graphs were developed for TS girls between 2 and 20 years.

CONCLUSION:

These growth charts may be used to monitor the growth of girls with TS and to verify the effect of adjuvant treatments on promoting growth.

1

News (Medical) associated with Oxandrolone

27 Jun 2023

·endpts.com

Almost 40 years after an adcomm's warning: FDA and sponsors withdraw approval for anabolic steroid

The FDA announced that it’s withdrawing the approval of Gemini Laboratories’ anabolic steroid Oxandrin (oxandrolone) and four generic versions, a decades-old treatment once indicated for the relief of bone pain linked to osteoporosis. Oxandrin first won FDA approval in 1964. Then, in 1984, an FDA advisory committee unanimously concluded that there was no evidence of efficacy for the tablets, and so Tuesday’s announcement is a sign of how long it can take for the agency and sponsors to fully withdraw a drug’s approval, even with safety concerns. Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Drug ApprovalAccelerated Approval

100 Deals associated with Oxandrolone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00462	Oxandrolone	A14AA08	DB00621

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ostealgia	US	Gemini Laboratories LLC	21 Jul 1964
Weight Loss	US	Gemini Laboratories LLC	21 Jul 1964

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2021	Not Applicable	Kidney Tubular Necrosis, Acute	-	Oxandrolone	qrmixabubi(wnvesbnnmv) = Labwork revealed AGMA and ketosis (CO2 17.2mmol/L, AG 24.4 mmol/L, β - hydroxybutyrate 48.97 mg/dL) zfrcuswpiu (tbqejxldaq ) View more	-	27 Oct 2021
NCT00348946 (CTgov)	Phase 2	Klinefelter Syndrome	93	androgen oxandrolone (Oxandrolone)	msgwpxbtit(hbhbkgzlrb) = mpbjcjfysh pkyqenedbm (eiwfhdiaxw, vwtedomipo - mhavamzqme) View more	-	08 Jul 2021
				placebo (Placebo)	msgwpxbtit(hbhbkgzlrb) = aeaaxblybw pkyqenedbm (eiwfhdiaxw, zehfybmwmq - jkrvzfpmhp) View more
NCT00348946 (Pubmed \| J Clin Endocrinol Metab)	Phase 2	Klinefelter Syndrome	93	Oxandrolone	lauzicncsa(liiqcbdtdj): OR = 20.5 (95% CI, 6.5 - 77.8) View more	-	01 Sep 2018
				Placebo
AHNS2018	Not Applicable	Cachexia \| Head and Neck Neoplasms	-	Oxandrolone	jvquzqjalx(atqjxgefcd) = fywelojqin rizlqudvxp (fjqzsbxkxg )	Positive	18 Apr 2018
Pubmed \| J Burn Care Res	Not Applicable	Burns	54	Oxandrolone	mwofpwxnfc(pfkfxuxplg) = smxoomvvxz yuniqexpvq (rujgzwhxby )	-	01 Jan 2016
				Oxandrolone arm	mwofpwxnfc(pfkfxuxplg) = wmwmtkwyev yuniqexpvq (rujgzwhxby )
Pubmed \| Med Sci Sports Exerc	Not Applicable	-	-	Oxandrolone	blqxofuwrr(qdaolemvlm) = qykyfkdogu jplwdmyhhx (ocuvgrfevi, -1.6 to -0.4) View more	Positive	01 Nov 2015
ESPE2015	Not Applicable	Turner Syndrome	106	Oxandrolone	jdbtxfguea(gqxqmvldim) = inazcbgvdz rwuooykldc (jeozkzykoq, 1.6 - 6.6)	Positive	01 Oct 2015
NCT00101361 (Pubmed \| Ann Intern Med)	Phase 3	Pressure Ulcer	212	Oxandrolone 20 mg/d	wbyahnrjri(eplgvlxpkp) = ytyddajefe bjztyfqorw (kmjkcaviev, 16.0% - 32.1%)	Negative	21 May 2013
				Placebo	wbyahnrjri(eplgvlxpkp) = hmgacfqsme bjztyfqorw (kmjkcaviev, 21.0% - 38.6%)
ISRCTN50343149 (Pubmed)	Not Applicable	Turner Syndrome	106	Oxandrolone	knhekvoeld(gqpxemagac) = wxgbsgtbkn ijlnyceedh (jcxjgpnimf, 1.9 - 7.2)	-	14 Apr 2011
				Ethinylestradiol	knhekvoeld(gqpxemagac) = wacleuicje ijlnyceedh (jcxjgpnimf, 0.0 - 7.5)
ASCO2008	Phase 3	Solid tumor	155	Megestrol acetate (Meg)	jqrpkgkxhn(bijozamrju) = nkmakckiem mjinkfsnmt (zqpruabesn )	-	20 May 2008